title: Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer.
abstract: BACKGROUND
  An alternative to completion thyroidectomy for well-differentiated thyroid carcinoma is to ablate the remnant lobe with 131 I. The purpose of this study is to review our own experience with large remnant ablation.
  
  
  METHODS
  A retrospective review of 169 patients with well-differentiated thyroid cancer treated at one institution over a 14-year period was undertaken. Seventy-one patients who underwent partial thyroidectomy (PT) followed by 131 I ablation were identified. This group was compared to 98 patients treated with total thyroidectomy (TT).
  
  
  RESULTS
  Mean follow-up was 6.2 years for the 71 PT + 131 I versus 4.7 years for the 98 TT patients (P = .184). Recurrence occurred in 4 of 71 PT + I 131 patients (5.6%) versus 9 of 98 TT patients (9.2%) (P = .393). Other than a tendency for the size of the primary to be slightly larger and for the histology to be follicular carcinoma in the PT + 131 I patients, the 2 groups were nearly identical in age, gender, and other prognostic factors such as capsular invasion and metastases.
  
  
  CONCLUSIONS
  Large-dose ablation with 131 I is a viable alternative to completion thyroidectomy. Recurrence rates over an average 6-year period are similar to TT. Long-term monitoring of these cohorts is required.
authors.affiliation: Department of Surgery, Division of Endocrinology, McGill University, Montreal, Quebec, Canada.
authors.forename: Guy
authors.initials: G
authors.lastname: Leblanc
authors.forename: Roger
authors.initials: R
authors.lastname: Tabah
authors.forename: Moishe
authors.initials: M
authors.lastname: Liberman
authors.forename: John
authors.initials: J
authors.lastname: Sampalis
authors.forename: Rami
authors.initials: R
authors.lastname: Younan
authors.forename: Jacques
authors.initials: J
authors.lastname: How
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy* / Q000601:surgery; D018249:Adenoma, Oxyphilic / Q000532:radiotherapy* / Q000601:surgery; D000368:Aged; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy* / Q000601:surgery; D018365:Neoplasm, Residual; D012189:Retrospective Studies; D013964:Thyroid Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes